Canada Markets closed

Aptose Biosciences Inc. (APS.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.08000.0000 (0.00%)
At close: 03:59PM EDT
Full screen
Previous Close1.0800
Open1.1000
Bid1.0800 x N/A
Ask1.1100 x N/A
Day's Range1.0700 - 1.1100
52 Week Range1.0000 - 4.3000
Volume12,051
Avg. Volume26,744
Market Cap96.065M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-0.7990
Earnings DateMar 21, 2022 - Mar 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.34
  • GlobeNewswire

    CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

    HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS), please note that in the section of updated clinical findings with HM43239, the fifth bullet point should read "Eight total responses, including seven CRs and one PR, and favorable

  • GlobeNewswire

    Aptose Presents Highlights from Corporate Update and KOL Event

    HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today released highlights from a key opinion leader (KOL) and corporate update

  • GlobeNewswire

    Aptose Biosciences Announces Results of Annual Meeting of Shareholders

    SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company’s annual and special meeting of shareholders held today, May 31, 2022 (the “Meeting”). A total of 53.46% of the common shares of the Company entitled to be voted were represented